Mixing cocaine and alcohol produces a substance your body did not prepare for.
When cocaine and alcohol are taken together, the liver produces a third compound called cocaethylene. It is more cardiotoxic than either substance alone, stays longer in the bloodstream, and intensifies both the craving cycle and the crash that follows. Jintara treats cocaine addiction with a therapy-led model that addresses polydrug use directly, including the clinical picture of cocaine and alcohol together.
- Cocaethylene is cardiotoxic: the combination raises sudden cardiac event risk substantially.
- Alcohol masks cocaine toxicity, making it harder to know when to stop.
- Dual withdrawal requires two separate clinical protocols happening simultaneously.
- No FDA-approved medication exists for cocaine; therapy drives recovery.
Fully Licensed Facility
Cocaethylene is the compound the liver produces when cocaine and alcohol are taken together.
Cocaethylene is a toxic compound the liver synthesises when cocaine and alcohol are metabolised together. The cocaine and alcohol interaction produces this third compound rather than a simple addition of the two substances' effects. Unlike cocaine itself, which clears relatively quickly, cocaethylene has a longer half-life and remains active in the bloodstream for a greater period. The result is a more sustained high, which is one reason the combination is so frequently repeated: it feels like it is extending the experience. What the person is experiencing is a third drug, not the sum of two.
The liver is now managing three active compounds simultaneously: cocaine, ethanol, and cocaethylene. Each has its own metabolic demands. The liver prioritises clearing ethanol above cocaine, which means cocaine lingers longer in the system than it would alone. This alters the intensity and duration of cocaine's effects in ways that are not predictable.
Cocaethylene's cardiac profile is what makes this combination clinically significant. Both cocaine and alcohol place stress on the cardiovascular system independently. Cocaethylene produces an additive effect that exceeds either substance in isolation, and peer-reviewed research on cocaethylene cardiotoxicity has consistently linked it to increased risk of arrhythmia and sudden cardiac events. The body is processing a compound it was not designed to produce.
Cocaine is one of several stimulant substances where combination with other drugs fundamentally changes the clinical risk profile.
Cocaine and alcohol are mixed so frequently because each appears to counteract what the other does wrong.
Cocaine is a stimulant: it raises pulse, temporarily lifts mood, and often produces anxiety, particularly at higher doses. Alcohol is a depressant: it slows reaction time, reduces inhibition, and at sufficient doses, produces sedation. From the user's perspective, alcohol smooths the rough edges of cocaine, and cocaine prolongs social availability before alcohol sedation sets in.
This apparent balance is pharmacologically real but misleading. Alcohol masks the warning signals that cocaine toxicity normally produces. Chest tightness, a raised pulse, and the anxiety that signals overuse are all suppressed by alcohol. The person continues using cocaine past the point where physical symptoms would ordinarily cause them to stop. The result is higher doses and longer sessions than either drug alone would produce.
The pattern is particularly common in professional contexts. Darren Lockie, Jintara's founder, describes a profile he sees repeatedly: "There's a very high level ranking executive in Hong Kong. He has six glasses of wine at lunch and then goes out at night and does two grams of cocaine. So whilst he's here for executive burnout, there are a lot of underlying issues contributing towards that."
The alcohol component carries its own clinical weight, including alcohol use disorder with its distinct withdrawal profile, requiring assessment separately from the cocaine presentation.
Cocaethylene places significantly higher cardiovascular stress on the body than cocaine alone.
The cardiovascular risk of cocaine is well established: vasoconstriction, raised blood pressure, accelerated pulse, and in some individuals, arrhythmias or coronary spasm. These effects are why cocaine is associated with cardiac events even in people without known cardiac disease. When alcohol is added, the combination does not simply stack these risks. Cocaethylene produces an additive cardiovascular effect that exceeds either substance in isolation. NIDA's cocaine research overview documents the cardiac risk profile in detail.
The risk is compounded by alcohol's masking effect. A person who would normally stop using cocaine when they notice chest tightness or palpitations may not perceive those signals clearly while drinking. Use continues past the physiological threshold where the risk is greatest.
Cocaine also carries a specific risk called coronary vasospasm, in which the arteries supplying the myocardium contract suddenly, reducing blood flow. Jintara's day-two medical assessment, conducted at Jintara's expense, includes an EKG alongside a full blood panel, liver function tests, kidney function, and chest X-ray. Any significant findings are reviewed by the team and, where necessary, referred to Bangkok Hospital Chiang Mai or RAM Hospital.
Cardiac monitoring is built into Jintara's medical detox process from the first day, not added reactively when a concern arises.
The psychological effects of cocaine and alcohol together are deeper and longer lasting than cocaine alone.
Cocaine's dopamine mechanism already damages baseline mood function: repeated use progressively depletes the brain's natural dopamine production capacity, which is why the cocaine crash feels so severe. When alcohol is added, two further mechanisms compound this. Alcohol alters serotonin and GABA signalling, both of which affect mood stability. And the extended high produced by cocaethylene means the dopamine depletion at the end of the session is greater than after cocaine alone. NIDA's DrugFacts on cocaine covers the neurological basis of the crash cycle and anhedonia.
The practical result is a crash that is both deeper and longer. People who have used cocaine and alcohol together consistently describe the day after as qualitatively worse: a flatter emotional state, more pronounced anxiety, greater difficulty concentrating, and more intense cravings. The craving cycle also accelerates. The longer the cocaethylene high, the more intense the signal when it drops, and the stronger the drive to use again.
Over time, this pattern deepens the development of anhedonia, the clinical term for the inability to experience pleasure from activities that previously produced it. Anhedonia is the central challenge in cocaine recovery. When alcohol use accompanies cocaine use, the anhedonic baseline tends to be lower and the recovery timeline longer, because both substances have been altering the brain's reward circuitry simultaneously.
In many cases, the flat emotional state and anxiety that emerge when both substances are stopped reveal an underlying dual diagnosis that the substances had been suppressing, and which becomes the primary clinical focus.
“Earlier on in treatment, if clients experience craving or agitation, we introduce coping skills they can use immediately. Distraction, the pool, the UNO game with the Thai staff. Later, we go deeper into what the substance was doing for them.
Withdrawing from cocaine and alcohol simultaneously involves two clinically separate processes.
Alcohol withdrawal and cocaine withdrawal are not the same clinical event. They require different monitoring protocols, different timelines, and different clinical priorities. When both are present, the treatment team manages two parallel processes, which is why polydrug presentations require specialist clinical environments.
Alcohol withdrawal carries genuine medical risk. Abrupt cessation in a dependent drinker can produce seizures, delirium tremens, cardiac arrhythmias, and potentially fatal outcomes, as documented in NCBI clinical guidance on alcohol withdrawal. Alcohol withdrawal is the clinical priority in any polydrug detox that includes alcohol. Jintara's nursing team monitors vital signs and assesses using the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar). Following the scale's standard clinical thresholds, clients scoring above 14 are reassessed every one to two hours. Clients who stabilise below 8 move to once-daily review.
Cocaine withdrawal, in contrast, does not carry seizure risk. It is primarily psychological: profound fatigue in the first 24 to 72 hours, hypersomnia, low mood, and anhedonia. But in a person who is also going through alcohol withdrawal, the psychological severity of the cocaine crash is experienced on top of the physical symptoms of alcohol withdrawal. The combination can produce a clinical presentation more distressing than either alone, with close monitoring required for mood instability, including suicidal ideation.
What the first week at Jintara looks like in practice, including the clinical sequence for polydrug presentations, is outlined for people preparing for admission.
Treatment for cocaine and alcohol together requires addressing both as primary, not one primary and one secondary.
A common clinical failure in polydrug treatment is hierarchical reasoning: identifying one substance as the primary problem and treating the second as a contributing factor. In cocaine and alcohol presentations, this consistently underperforms. A person whose cocaine use is tightly coupled with social drinking will find that the alcohol remains intact when they complete a cocaine-focused program, and vice versa. The driver that sustains one substance's use also sustains the other.
At Jintara, assessment begins on day two with a full psychiatric evaluation covering both substances: use history, frequency, the sequence in which they are typically used together, the contexts that trigger use, and the emotional states that precede each. This produces a treatment plan that addresses both the cocaine neurology and the alcohol neurology simultaneously.
There is no FDA-approved pharmacotherapy for cocaine addiction. Cognitive behavioural therapy is the most evidence-supported psychological intervention for cocaine use disorder and is also one of the supported approaches for alcohol use disorder, as referenced in SAMHSA's clinical guidance on substance use treatment. For clients presenting with both, the therapy structure works across both substances simultaneously, addressing the thought patterns and triggers that drive each.
The full structure of Jintara's treatment program describes how CBT, DBT, and other modalities are integrated into the 30-day program and applied to polydrug presentations.
“Whilst someone might arrive presenting as executive burnout, once we do the full assessment, we often find cocaine, alcohol, and a lot of underlying issues contributing to both.
Jintara's clinical approach to cocaine and alcohol begins with two tracks, not one.
Jintara is a residential program for adults over 25, with a maximum of ten clients at any time and a staff ratio of 3.2 to one. Three therapists work within the program alongside nursing staff on awake overnight coverage and a consulting psychiatrist who reviews every client. This structure matters for polydrug presentations because the clinical contact required to run two parallel treatment tracks is only possible at small scale.
For cocaine and alcohol clients, medical stabilisation comes first, addressing alcohol withdrawal under nursing supervision and CIWA-Ar monitoring. As the medical picture stabilises, usually by day three to five in moderate presentations, the therapy track begins in parallel. Individual CBT sessions address both substances, identifying the cognitive patterns that link cocaine and alcohol use and the specific triggers for each.
Where trauma drives the pattern, which is frequently the case in high-functioning professionals managing stress or unprocessed experiences, EMDR therapy is available. EMDR is not automatically assigned; it is introduced after medical and psychological stabilisation. Jintara's fitness program, led by Tong, begins as early as day two or three for medically stable clients and serves as the primary behavioural activation tool targeting the dopamine deficit both substances leave behind.
For clients where trauma is part of the cocaine and alcohol pattern, the clinical team discusses whether EMDR therapy is appropriate and, if so, when it is introduced within the 30-day structure.
Cocaine and alcohol are not one problem with two parts. They are two problems that have learned to need each other.
The framing that often brings people to treatment is "I have a cocaine problem." The alcohol is presented as incidental, the social context in which the cocaine happens, rather than as a co-primary substance with its own dependence pattern. This is understandable, but clinically misleading, and it is one reason some people complete cocaine treatment and return to the same pattern within months.
Cocaine and alcohol use that has become entangled over years develops a mutual logic. The cocaine manages what alcohol cannot; the alcohol manages what cocaine cannot. The anhedonia, anxiety, and flatness of cocaine abstinence feel manageable when alcohol is still present. The reverse also applies: the agitation and low mood of early alcohol recovery can drive cocaine use as a mood management response.
Breaking the interlocked pattern requires working with both simultaneously and identifying what each substance was doing. At Jintara, that process begins in week one with the psychiatric assessment and continues across the 30-day program. The goal is not simply abstinence. It is understanding why each substance was necessary, and what needs to be in place for that need to be met a different way.
Jintara is a non-12-step program. The approach does not involve giving up control to a higher power. It involves understanding the pattern and building the clinical skills to live without it. The full range of conditions Jintara treats is on the what we treat page.
Talk with Our Admissions Team
Common Questions About Cocaine and Alcohol
The liver produces a compound called cocaethylene, which is more cardiotoxic than either cocaine or alcohol alone and stays in the bloodstream longer. This extends the high, masks the warning signals cocaine toxicity normally produces, and creates a deeper crash when both substances clear. The combination places greater cardiovascular stress on the body than cocaine alone.
Yes. Research links cocaethylene to increased risk of arrhythmia and sudden cardiac events. The cardiovascular risk is higher than cocaine alone because cocaethylene adds its own cardiotoxic action on top of cocaine and alcohol's independent cardiovascular effects. The risk does not scale predictably with dose.
Cocaethylene has a longer half-life than cocaine. It remains detectable in the bloodstream longer than cocaine after the last use, which is why the combined high feels more sustained. The exact duration depends on quantities used, liver function, and individual metabolic rate, but it is consistently longer than cocaine alone.
In the first 24 to 72 hours, most people experience profound fatigue, low mood, difficulty sleeping despite exhaustion, and intense cravings. Those who are also alcohol-dependent experience physical withdrawal symptoms simultaneously: agitation, sweating, tremor, and, in dependent drinkers, seizure risk. The combination of both processes produces a clinical picture more distressing than either alone.
Yes, for two reasons. Alcohol lowers inhibition and impairs the decision-making that supports abstinence, particularly in social contexts where cocaine has historically been used. And the emotional flatness of early cocaine recovery can drive alcohol use as a coping response, with the reverse also true. People stopping both simultaneously face a combined craving and withdrawal pattern that is harder to manage without professional support.
Yes, but it requires a medically supervised setting. Alcohol withdrawal carries seizure risk and must be monitored with the CIWA-Ar scale. Cocaine withdrawal does not carry that same risk but produces significant psychological distress that also requires support. A residential program with awake nursing overnight and a consulting psychiatrist is the appropriate clinical setting for this presentation.
Yes. Polydrug presentations, including cocaine and alcohol together, are among the most common profiles at Jintara. The program is designed to address multiple substances simultaneously rather than treating one as primary. Assessment on day two covers both, and the therapy track addresses both substances, their cognitive drivers, and the underlying factors that connect them.
Jintara is a small adult residential rehab in Chiang Mai with a 3.2:1 staff-to-client ratio. Polydrug presentations, including cocaine and alcohol together, are addressed with two parallel clinical tracks from the first day of treatment.
Jintara Rehab is licensed by the Thai Ministry of Public Health as a rehabilitation centre. The clinical information on this page describes Jintara's general approach to supporting clients during the early recovery period. Medical decisions, including medication protocols, are determined by addiction-specialist psychiatrists through our partner hospital pathway. Individual treatment varies based on clinical assessment. This content is for informational purposes and does not constitute medical advice.